ClinicalTrials.gg
RecruitingNCT07286123Updated Dec 16, 2025

Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)

An observational study in Gender Dysphoria, Adult, sponsored by University Hospitals Cleveland Medical Center. Recruiting at 1 site in United States. Open to male participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by University Hospitals Cleveland Medical Center · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
19 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.

Planned enrollment
9th of 16
20 · median 46
Started
2025
with 3 others
Observational
16 of 31
5 open now
Primary completion
2027-06
later than 6 of 12 live
Registered
28th of 31
by date

Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2025, is one of 16 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 28th registered.

Gender Dysphoria

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

Browse Gender Dysphoria studies →

Open to participants now

11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gender Dysphoria with a site in United States, or all of them as a file.
02

Study summary

Bottom gender affirming surgery is one of the key steps towards aligning the physical appearance and gender identity in transgender women. This surgery not only helps in reducing gender dysphoria but also significantly improves the quality of life and psychological well-being of the patients. The basic steps of bottom surgery typically involve the creation of a vagina using the skin from genital organs like the testes and penis, construction of the clitoris and labia. This complex surgery aims to create a functional and aesthetically pleasing vaginal canal that allows for sexual activity, urinary function, and a natural appearance.

As part of routine care, a special graft (skin-like material) called Kerecis™ is used to line the middle part of the vagina. It is made from North Atlantic cod skin that is treated in the laboratory and made suitable for surgery purposes. It can be used instead of skin. This graft has been given permission by the Food and Drug Administration (FDA) for marketing the US.

This study aims to identify changes in healing parameters following Kerecis™ based vaginoplasty. Up to 20 participants for this study.

Participants will be asked to fill out study questionnaires during follow-up visits at post-op week 2, week 12, month , and year 1.

At the 6 month post-op follow up, punch biopsies will be obtained from the deepest part, middle part, and the vaginal part most near to the vaginal opening parts to check the healing process using a microscope. The punch biopsies will be 1/8th inch x 1/8th inch each.

03

Conditions studied

  • Gender Dysphoria, Adult

Browse trials for

Keywords

  • xenograft
  • gender affirming vaginoplasty
  • bottom surgery
04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals requiring graft-based vaginoplasty

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19-99
  • Transgender women planning for gender affirming robotic vaginoplasty with TAPCap technique

Exclusion criteria

Exclusion Criteria:

  • Patients requiring Kerecis for Revision Vaginoplasty
  • Surgery candidates having Zero depth vaginoplaty (ZDV)
  • Non-Gender Affirming Vaginoplasty
  • Cases requiring the utilization of off-the-shelf grafts other than Kerecis
  • Allergy to fish products
  • Allergy to local anesthetic (1% lidocaine with epinephrine injection)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Individuals receiving vaginoplasty

    Individuals requiring graft-based vaginoplasty

    Procedure: Tubularized augmented peritoneal cap vaginoplasty · Procedure: Biopsy

Interventions

  • ProcedureTubularized augmented peritoneal cap vaginoplasty

    In this surgery, the distal portion of the neovagina is constructed using inverted penile skin, the proximal portion is made of peritoneal tissue. The area in between peritoneal tissue and penile skin is lined with the Kerecis graft in this standard of care surgery.

  • ProcedureBiopsy

    Biopsies will be obtained at 6 months post-op from the distal, middle, and proximal portions of the neovagina.

06

What researchers measure

Primary outcomes

  1. Degree of Neovaginal Epithelialization

    Degree of epithelialization of each sample biopsy. Biopsies are obtained from the proximal segment (peritoneal portion), middle segment (Xenograft portion), and, distal segment (penile skin portion) of the neovagina. Grade 0: No epithelialization Grade 1 : Minimal epithelialization Grade 2: Moderate epithelialization Grade 3: Significant epithelialization

    Time frame: Six months post-op

  2. Change in Vaginal Diameter

    The participants' vaginal diameter is calculated based on the largest tolerated vaginal dilator size (Soul Source; CA, USA) . Measurements are reported in centimeters (cm).

    Time frame: Post-op week 2, week, 12, month 6, and year 1

  3. Change in Vaginal Depth

    The participants' vaginal depth are calculated based on the largest tolerated vaginal dilator (Soul Source, CA, USA). Measurements are reported in centimeters (cm).

    Time frame: Post-op week 2, week, 12, month 6, and year 1

  4. Change in quality of life as measured by the Short-Form 36 (SF-36)

    This is a validated questionnaire measuring health-related quality of life through eight domains, covering physical and mental well-being. It's widely used in healthcare to assess overall health perception and functional status. With higher scores indicating greater quality of life.

    Time frame: Week 2, Week 12, Month 6, and year 1 post-op

  5. Change in Pain as measured by the Brief Pain Inventory - Short Form (BPI-SF)

    This is a concise validated questionnaire used to evaluate the severity and impact of pain experienced by individuals. It consists of questions that assess the intensity of pain at its worst, least, average, and current levels, as well as its interference with various aspects of daily life such as general activity, mood, walking ability, work, relationships, and enjoyment of life. Higher scores indicate worse outcomes.

    Time frame: Week 2, Week 12, Month 6, and year 1 post-op

  6. Change in Pain as measured by the The Female Genitourinary Pain Index (GUPI)

    This is a validated questionnaire used to assess symptoms related to genitourinary pain in women. It includes questions covering pain severity, urinary symptoms, and impact on quality of life, providing clinicians with a standardized tool to evaluate and monitor participants' symptoms and treatment responses in these chronic pain conditions. Higher scores indicate worse outcomes.

    Time frame: Week 2, Week 12, Month 6, and year 1 post-op

  7. Change in overall perception of improvement as measured by the PGI-I (Patient Global Impression of Improvement)

    This is a patient-reported scale that measures how individuals perceive their overall improvement after treatment, offering clinicians insight into treatment effectiveness from the participant's viewpoint. Lower scores indicate better outcomes.

    Time frame: Week 2, Week 12, Month 6, and year 1 post-op

  8. Change in sexual function of improvement as measured by the Female Sexual Function Index (FSFI)

    This is a validated 19-item questionnaire assessing six domains of female sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain. Each domain is scored, and the total score reflects overall sexual function, with higher scores indicating better function. It is used in clinical and research settings to evaluate sexual health and the impact of treatments. Higher scores indicate better outcomes.

    Time frame: Month 6, and year 1 post-op

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 16, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07286123
Collaborators
Kerecis Ltd.
Responsible party
Shubham Gupta (Professor, University Hospitals Cleveland Medical Center) — Principal investigator
First posted
Dec 16, 2025
Start date
Jul 22, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Dec 16, 2025

Study contacts

Seyed Sajjad Tabei, MD
Contact
seyedsajjad.tabei@uhhospitals.org
216-844-8963
Shubham Gupta, MD
principal investigator · University Hospitals Cleveland Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion